GRAL
GRAIL, Inc. Common StockGRAL
GRAL
About: GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Employees: 1,000
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
106% more call options, than puts
Call options by funds: $9.3M | Put options by funds: $4.51M
71% more capital invested
Capital invested by funds: $279M [Q3] → $476M (+$197M) [Q4]
55% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 49
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
8.84% more ownership
Funds ownership: 70.39% [Q3] → 79.23% (+8.84%) [Q4]
6% more funds holding
Funds holding: 302 [Q3] → 321 (+19) [Q4]
8% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 78
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
24%
downside
Avg. target
$26
2%
downside
High target
$32
21%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Canaccord Genuity Kyle Mikson 32% 1-year accuracy 9 / 28 met price target | 21%upside $32 | Buy Initiated | 21 Apr 2025 |
Morgan Stanley Tejas Savant 21% 1-year accuracy 4 / 19 met price target | 24%downside $20 | Equal-Weight Maintained | 18 Mar 2025 |
Financial journalist opinion
Based on 3 articles about GRAL published over the past 30 days
Positive
Barrons
12 hours ago
This Cancer Test Could Become Routine—and a Big Seller, Says Analyst
Grail stock will increase at least 20% over the next year, projects Canaccord's Kyle Gibson.
Positive
Seeking Alpha
1 week ago
GRAIL's Galleri Progresses While Back In Accumulation Levels
GRAL's Galleri test is easily its main value driver at this point. This test can screen over 50 cancers with high sensitivity and accuracy. Post-spin-off from Illumina, GRAL has continued growing its revenues while also securing partnerships like Quest Diagnostics and TRICARE. GRAL's Galleri also secured the FDA's Breakthrough Device status, and its pivotal PMA submission should happen by 1H2026.
Positive
Seeking Alpha
1 week ago
How Does GRAIL Benefit From The Proposed MCED Legislation?
GRAIL, Inc.'s Galleri test could see significant revenue growth if the bipartisan MCED bill passes, enabling Medicare reimbursement for FDA-approved multi-cancer early detection tests. Galleri's potential market includes 67 million Medicare beneficiaries, with a conservative estimate of $2.4 billion in revenue by the fifth year post-legislation. Despite promising financials and market leadership, Galleri's FDA approval is pending, and Medicare reimbursement may not start until 2028, posing short-term risks.
Neutral
PRNewsWire
1 month ago
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Feb. 26, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 108,450 shares of GRAIL's common stock to 15 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.
Neutral
PRNewsWire
1 month ago
GRAIL Partners With Actress Kate Walsh for Generation Possible to Raise Awareness of Multi-Cancer Early Detection Testing
MENLO PARK, Calif. , Feb. 25, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, has partnered with award-winning actress Kate Walsh to launch Generation Possible, an educational initiative to raise awareness of multi-cancer early detection (MCED) testing.
Neutral
PRNewsWire
1 month ago
GRAIL to Present at TD Cowen 45th Annual Health Care Conference
MENLO PARK, Calif. , Feb. 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, Mar. 4 at 9:10 a.m.
Neutral
Seeking Alpha
1 month ago
GRAIL, Inc. (GRAL) Q4 2024 Earnings Call Transcript
GRAIL, Inc. (NASDAQ:GRAL ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Bob Ragusa - Chief Executive Officer and Board Member Aaron Freidin - Chief Financial Officer Joshua Ofman - President Sir Harpal Kumar - President of International Business and BioPharma Conference Call Participants Doug Schenkel - Wolfe Research Operator Good day, ladies and gentlemen, and welcome to the GRAIL Fourth Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.
Neutral
PRNewsWire
1 month ago
GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results
Sold More than 137,000 Galleri® Tests in 2024, Growing U.S. Galleri Revenue 45% Year-Over-Year to $108.6 Million Completed Study Visits for Two Registrational Studies in July to Support Modular PMA Submission for Galleri On Track for Continued Commercial Growth in 2025 with TRICARE Coverage and Recent Announcement of Quest Integration Moderated Cash Burn, Ending 2024 with a Cash Position of $767M, Extending Runway into 2028 MENLO PARK, Calif. , Feb. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2024 and provided business updates.
Neutral
PRNewsWire
2 months ago
GRAIL to Announce Fourth Quarter 2024 Financial Results
MENLO PARK, Calif. , Feb. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter 2024 following the close of market on Thursday, Feb. 20, 2025.
Neutral
PRNewsWire
2 months ago
GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System
GRAIL's Galleri Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience MENLO PARK, Calif. and SECAUCUS, N.J.
Charts implemented using Lightweight Charts™